• In late July 2026, Thermo Fisher Scientific highlighted a series of recent diagnostic product launches and FDA clearances at the ADLM conference in Anaheim, alongside strong second-quarter results with US$11.99 billion in sales and US$1.74 billion in net income.
• The combination of expanded specialty diagnostics offerings, such as the EXENT multiple myeloma platform and EliA CTD 13 autoimmune assay, and efficiency-focused tools like LabLink360 and InstaFlux underscores Thermo Fisher’s push to deepen its role in critical clinical and food testing workflows.
• We’ll now examine how Thermo Fisher’s new FDA-cleared EXENT multiple myeloma platform may influence the company’s broader investment narrative.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher, you generally need to believe in steady demand for high‑end tools and services across pharma, diagnostics and applied markets, supported by disciplined cost control. The latest ADLM product launches and solid Q2 2026 results (US$11.99 billion in sales, US$1.74 billion in net income) reinforce the innovation story but do not fundamentally change the near term picture, where China exposure and margin pressure in Analytical Instruments remain key risks.

Among the recent announcements, the FDA 510(k) clearance and broad rollout of the EXENT multiple myeloma platform look most relevant here. EXENT fits squarely into the long term catalyst of high impact innovation in specialty diagnostics, adding a differentiated tool in hematology where reliable monitoring is critical. If adoption ramps, it could deepen Thermo Fisher’s role in clinical workflows and support the case that new platforms can offset softer academic and government demand elsewhere.

Yet, even with these wins, investors should be aware that ongoing tariff exposure and China weakness could still...

Thermo Fisher Scientific's narrative projects $54.1 billion revenue and $9.5 billion earnings by 2029. This requires 6.2% yearly revenue growth and about a $2.7 billion earnings increase from $6.8 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $590.77 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Thermo Fisher could reach around US$56.4 billion in revenue and US$10.3 billion in earnings, which is far more bullish than consensus and sits in sharp contrast to concerns about trade tensions and China headwinds; this new diagnostics news could either support that optimistic view or push expectations closer to the more cautious camp, so it is worth considering where you personally sit between these very different outlooks.

Explore 5 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth as much as 22% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.